Skip to main content
HCPCS J3285 · Level II · Part B drug

J3285: treprostinil (Remodulin), HCPCS Level II J code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for J3285

Billing unit
1 MG
Treprostinil injection
ASP payment limit
$54.563
October 2026; -0.3% vs July 2026
Practitioner MUE
1
MAI 3
OPPS status
SI K
APC 1701
NCCI exposure
no PTP pairs
Coverage articles
0
none list this code

TL;DR

HCPCS J3285 is the Level II code for Injection, treprostinil, 1 mg, billed per 1 MG. The Medicare Part B ASP payment limit for October 2026 is $54.563 per billing unit, down 0.3% from July 2026. The practitioner MUE allows up to 1 units per date of service (MAI 3), so a full 1-unit day is $54.56 at the current limit. Under OPPS it carries status indicator K in APC 1701. With a 1 mg billing unit, a single administration can be hundreds of units; the unit count on the claim must equal the milligrams given, and rounding rules for partial units follow the contractor's guidance. Other HCPCS codes whose descriptor names treprostinil: J7686 (Tyvaso; inhalation route; solution, unit dose; billed per 1.74 mg). The ASP crosswalk maps 17 NDCs to it, sold as Treprostinil Injection, Remodulin by Teva Parenteral Medicines, Inc., Sandoz Inc., Dr. Reddy's Laboratories Inc. No current Billing and Coding Article lists J3285, so coverage follows the FDA label, compendia and any applicable NCD.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for J3285 at $54.563 per 1 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $54.74 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for J3285
QuarterPayment limitPerCoinsurance
October 2026$54.5631 MG20%
July 2026$54.741 MG—
Source: CMS Medicare Part B Drug Payment Limit File. Commercial and Medicaid payers set their own rates.

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 17 NDCs from 4 labelers to J3285. Report the NDC in the claim's drug segment and bill the number of J3285 units that equals the quantity administered divided by 1 MG; the last column gives units per full package.

NDCs that crosswalk to J3285
NDCDrug nameLabelerPackage sizeBilling units / package
00703-0666-01Treprostinil InjectionTeva Parenteral Medicines, Inc.20 × 120
00703-0676-01Treprostinil InjectionTeva Parenteral Medicines, Inc.20 × 150
00703-0686-01Treprostinil InjectionTeva Parenteral Medicines, Inc.20 × 1100
00703-0696-01Treprostinil InjectionTeva Parenteral Medicines, Inc.20 × 1200
00781-3420-80Treprostinil InjectionSandoz Inc.20 × 120
00781-3425-80Treprostinil InjectionSandoz Inc.20 × 150
00781-3427-80Treprostinil InjectionSandoz Inc.20 × 1100
00781-3430-80Treprostinil InjectionSandoz Inc.20 × 1200
43598-0646-11Treprostinil InjectionDr. Reddy's Laboratories Inc.20 × 150
43598-0647-11Treprostinil InjectionDr. Reddy's Laboratories Inc.20 × 1100
43598-0648-11Treprostinil InjectionDr. Reddy's Laboratories Inc.20 × 1200
43598-0649-11Treprostinil InjectionDr. Reddy's Laboratories Inc.20 × 120
66302-0101-01RemodulinUnited Therapeutics Corporation20 × 120
66302-0102-01RemodulinUnited Therapeutics Corporation20 × 150
66302-0105-01RemodulinUnited Therapeutics Corporation20 × 1100
66302-0110-01RemodulinUnited Therapeutics Corporation20 × 1200
66302-0114-01RemodulinUnited Therapeutics Corporation20 × 18

Medically Unlikely Edits (MUE)

CMS publishes 2 MUE values for J3285. For practitioners the limit is 1 unit per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.

MUE values for J3285 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services13 Date of Service Edit: ClinicalClinical: CMS Workgroup
Facility outpatient hospital93 Date of Service Edit: ClinicalPrescribing Information

MUE for J3285 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists J3285 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check J3285 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

J3285 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

No current Billing and Coding Article lists J3285 in its HCPCS table. Coverage then follows the drug's FDA label, compendia and any National Coverage Determination; check the Medicare Coverage Database before administering off-label.

Local coverage policies that list J3285

1 active Local Coverage Determination lists J3285 in the policy or in its billing and coding article. Each applies only in its contractor's jurisdiction; check the one for the state where the drug is administered.

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, J3285 carries status indicator K and is assigned to APC 1701, with a published national unadjusted payment of $54.563. Status K means the drug is paid separately under OPPS at the ASP-based rate rather than packaged into the procedure.

Ambulatory surgical center (ASC) payment

In the October 2026 ASC Addendum BB (covered ancillary services), J3285 carries payment indicator K2, which CMS defines as "Drugs, biologicals, and radiopharmaceuticals paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS rate". The national ASC payment is $54.56 per 1 MG, paid only when the drug is furnished integral to a covered surgical procedure.

Common denials for J3285 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for J3285

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS J3285

What does HCPCS code J3285 describe?

J3285 is defined by CMS as "Injection, treprostinil, 1 mg". Each billing unit represents 1 MG, so the units reported on the claim must equal the dose administered divided by that unit.

Is J3285 a CPT code?

No. J3285 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as treprostinil (Remodulin); CPT codes are five-character codes maintained by the AMA. On a Part B claim J3285 reports the drug itself in 1 mg units, and the administration is billed on its own line.

What is the Medicare reimbursement for J3285 in October 2026?

The ASP-based payment limit is $54.563 per 1 MG, with 20% beneficiary coinsurance. The July 2026 limit was $54.74. Commercial payers use their own fee schedules.

How many units of J3285 can be billed per day?

The practitioner Medically Unlikely Edit is 1 units per date of service with adjudication indicator 3 (Date of Service Edit: Clinical). The facility outpatient MUE is 9. MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "Clinical: CMS Workgroup" as the rationale.

Which NDCs map to J3285?

The October 2026 ASP crosswalk lists 17 NDCs from 4 labelers: Treprostinil Injection (Teva Parenteral Medicines, Inc.); Treprostinil Injection (Sandoz Inc.); Treprostinil Injection (Dr. Reddy's Laboratories Inc.); Remodulin (United Therapeutics Corporation). For example NDC 00703-0666-01 (package size 20) equals 20 billing units of J3285.

Does J3285 have NCCI bundling edits?

No active practitioner PTP pairs list J3285 as a column-1 or column-2 code in the v323r0 release.

J3285 vs J7686: what is the difference?

Both are HCPCS Level II codes whose descriptor names treprostinil. What sets J7686 apart: Tyvaso; inhalation route; solution, unit dose; billed per 1.74 mg. J3285 is billed per 1 mg, limit $54.563, MUE 1; J7686 is billed per 1.74 mg, limit $830.383, MUE 1. Report the code whose descriptor matches the product and setting in the record.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.